```html

MALT Lymphoma – A Complete Patient‑Friendly Guide

Overview

Mucosa‑associated lymphoid tissue (MALT) lymphoma is a type of low‑grade (indolent) non‑Hodgkin B‑cell lymphoma that originates in the lymphoid tissue that lines various mucosal surfaces of the body. Although it can appear in many organs, the most common sites are the stomach, salivary glands, thyroid, lung, ocular adnexa (tissues around the eye), and the gastrointestinal tract.

Who it affects: MALT lymphoma is most frequently diagnosed in adults between 50 and 70 years of age, with a slight female predominance (≈55 % of cases). However, it can occur at any age, including in children with autoimmune conditions.

Prevalence: In the United States, MALT lymphoma accounts for about 7‑8 % of all non‑Hodgkin lymphomas, translating to roughly 4,000–5,000 new cases each year (SEER database, 2020). Worldwide incidence varies, reflecting differences in Helicobacter pylori infection rates and other regional risk factors.

Symptoms

Because MALT lymphoma grows slowly, many patients are asymptomatic at diagnosis. When symptoms appear, they depend on the organ involved. Below is a comprehensive list categorized by location.

Gastrointestinal (most common)

• Abdominal discomfort or mild pain – often vague and intermittent.
• Unexplained weight loss – usually modest (5–10 % of body weight).
• Nausea or early satiety – feeling full after a small amount of food.
• Gastric ulcer‑like symptoms – burning sensation, bloating.
• Occult gastrointestinal bleeding – may present as iron‑deficiency anemia.

Salivary glands (e.g., parotid)

• Persistent, painless swelling of one or both glands.
• Dry mouth (xerostomia) due to reduced saliva production.
• Frequent sore throats or difficulty swallowing.

Thyroid

• Enlarged, firm thyroid nodule.
• Hoarseness or a feeling of pressure in the neck.
• Rarely, compressive symptoms such as difficulty breathing.

Lung (pulmonary MALT)

• Chronic cough (dry or productive).
• Shortness of breath on exertion.
• Occasional chest discomfort.

Ocular adnexa (orbit, eyelid)

• Painless swelling or mass around the eye.
• Redness, tearing, or mild vision changes.

Systemic (“B‑symptoms”)

• Fever >38 °C (100.4 °F) without infection.
• Night sweats that soak sleepwear.
• Unexplained weight loss >10 % of body weight over 6 months.

Most people never develop B‑symptoms because MALT lymphoma progresses slowly, but their presence should prompt a more urgent evaluation.

Causes and Risk Factors

Unlike aggressive lymphomas, MALT lymphoma is strongly linked to chronic antigenic stimulation—persistent infection or autoimmune inflammation that causes lymphoid tissue to accumulate in mucosal sites.

Infectious agents

• Helicobacter pylori – the leading cause of gastric MALT lymphoma. Eradication of H. pylori leads to remission in up to 80 % of early cases.<sup>[1] Mayo Clinic</sup>
• Chronic hepatitis C virus (HCV) – associated with splenic and hepatic MALT lymphoma.
• Campylobacter jejuni – linked to immunoproliferative small‑intestinal disease (IPSID), a variant of MALT lymphoma.
• Chlamydophila psittaci – implicated in ocular‑adnexal MALT lymphoma.

Autoimmune diseases

• Sjögren’s syndrome – most common non‑infectious association; up to 10 % of Sjögren’s patients develop salivary‑gland MALT lymphoma.<sup>[2] Cleveland Clinic</sup>
• Hashimoto thyroiditis – increases risk of thyroid MALT lymphoma.
• Systemic lupus erythematosus, rheumatoid arthritis – modestly elevated risk.

Other risk factors

• Age >50 years (the risk rises with age).
• Female sex (slightly higher incidence).
• Geographic regions with high H. pylori prevalence (Asia, Eastern Europe).
• Family history of lymphoid malignancies (rare, but contributes to susceptibility).

Diagnosis

Diagnosis involves a combination of clinical suspicion, imaging, endoscopic evaluation, and tissue biopsy. Because MALT lymphoma mimics benign inflammatory lesions, histopathologic confirmation is essential.

Initial work‑up

• History & physical examination – focus on organ‑specific symptoms and risk factors (e.g., H. pylori infection, autoimmune disease).
• Laboratory tests – complete blood count, liver/kidney function, serum electrolytes, lactate dehydrogenase (LDH), beta‑2 microglobulin, and H. pylori serology or stool antigen.

Imaging studies

• Upper gastrointestinal endoscopy with targeted biopsies for gastric disease.
• CT scan (chest/abdomen/pelvis) – evaluates lymph node involvement and organ masses.
• PET‑CT – useful for staging and detecting metabolically active disease, though low‑grade lymphoma may be PET‑avid.
• Ultrasound – for superficial salivary‑gland or thyroid lesions.

Pathology

• Biopsy – core needle or excisional biopsy yields tissue for microscopic analysis.
• Immunohistochemistry (IHC) – neoplastic cells are CD20+, CD79a+, BCL2+, and negative for CD5, CD10, and cyclin D1 (helps differentiate from other B‑cell lymphomas).
• Genetic studies – detection of translocations t(11;18)(q21;q21) (API2‑MALT1) predicts resistance to H. pylori eradication therapy.

Staging

The Lugano modification of the Ann Arbor system is the accepted staging method for extranodal lymphomas:

• Stage I – disease confined to a single extralymphatic organ.
• Stage II – involvement of the primary site plus regional lymph nodes.
• Stage III – disease on both sides of the diaphragm.
• Stage IV – disseminated involvement of distant organs or bone marrow.

Treatment Options

MALT lymphoma’s indolent nature allows for a personalized, often less aggressive approach. Treatment selection depends on stage, site, presence of specific genetic lesions, and patient comorbidities.

1. Antibiotic eradication (first‑line for gastric MALT)

• Standard regimen – triple therapy (PPI + amoxicillin + clarithromycin) for 14 days, or bismuth quadruple therapy if resistance is suspected.
• Response rates: 70‑80 % achieve complete remission (CR) when t(11;18) is absent.<sup>[3] NIH</sup>

2. Radiotherapy

• Low‑dose (24–30 Gy) external beam radiation is highly effective for localized (stage I–II) disease in the stomach, orbit, thyroid, or salivary glands.
• 5‑year local control >95 % with minimal toxicity.

3. Immunochemotherapy

Reserved for advanced stage, refractory disease, or sites where radiation is impractical.

• Rituximab monotherapy (anti‑CD20 monoclonal antibody) – overall response ≈70 %.
• Rituximab ± bendamustine** – higher response rates (80‑90 %) with acceptable safety.
• Standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) is generally avoided because MALT lymphoma is usually chemo‑sensitive but not chemo‑dependent.

4. Targeted agents

• Ibrutinib (BTK inhibitor) – emerging option for relapsed/refractory disease.
• Lenalidomide + rituximab – studied in phase II trials with promising activity.

5. Surgical resection

Rarely needed today; may be considered for isolated, symptomatic gastric lesions that do not respond to antibiotics.

6. Lifestyle and supportive measures

• Eradication of H. pylori and any other identified infection.
• Management of underlying autoimmune disease (e.g., hydroxychloroquine for Sjögren’s).
• Nutrition counseling—especially after gastric radiation or resection.

Living with MALT Lymphoma

Even after successful treatment, regular follow‑up is essential because late relapses can occur (up to 10 % after 5 years).

Follow‑up schedule

• Every 3–6 months for the first 2 years: physical exam, CBC, LDH, and imaging as indicated.
• Annually thereafter, with endoscopic surveillance for gastric cases.

Practical daily‑life tips

• Stay hydrated and maintain a balanced diet – particularly important after gastric treatment.
• Monitor for new symptoms—any unexplained abdominal pain, persistent cough, or swelling should be reported promptly.
• Vaccinations – if you receive immunosuppressive therapy (e.g., rituximab), get inactivated flu vaccine annually and pneumococcal vaccine per CDC guidelines.
• Exercise – moderate activity (walking, swimming) improves fatigue and overall well‑being.
• Psychosocial support – join a lymphoma support group or seek counseling; anxiety is common after a cancer diagnosis.

Prevention

Because many risk factors are non‑modifiable, prevention focuses on reducing controllable triggers.

• Screen and treat H. pylori infection – testing (urea breath test, stool antigen, or endoscopic biopsy) and eradication therapy dramatically lower gastric MALT lymphoma risk.<sup>[4] WHO</sup>
• Manage autoimmune disorders – regular follow‑up with rheumatology/endocrinology to keep disease activity low.
• Limit chronic inflammation – avoid smoking, limit alcohol, and treat chronic infections promptly.
• Healthy lifestyle – balanced diet rich in fruits/vegetables, regular exercise, and maintaining a healthy weight can improve overall immune function.

Complications

If left untreated or inadequately controlled, MALT lymphoma can lead to:

• Progression to high‑grade lymphoma (e.g., diffuse large B‑cell lymphoma) in 5‑10 % of cases.
• Organ‑specific complications:
  • Gastric ulceration, bleeding, or perforation.
  • Obstructive jaundice from biliary involvement.
  • Vision loss or eye‑muscle dysfunction in orbital disease.
• Secondary infections due to immunosuppressive therapy (especially with rituximab or chemotherapy).
• Long‑term side effects of radiation (gastric ulcer, mild nausea, rare secondary malignancies).

When to Seek Emergency Care

---

References

1. Mayo Clinic. “MALT lymphoma (extranodal marginal zone B-cell lymphoma).” Updated 2023.
2. Cleveland Clinic. “Sjogren’s syndrome and cancer risk.” 2022.
3. National Cancer Institute. “Helicobacter pylori infection and gastric MALT lymphoma.” 2021.
4. World Health Organization. “Guidelines for the diagnosis, treatment and monitoring of H. pylori infection.” 2022.
5. American Cancer Society. “Non‑Hodgkin lymphoma survival and statistics.” 2023.

```